CDK9 inhibitors push cancer cells over the edge

Matthew W Nowicki; Malcolm D Walkinshaw

doi:10.1016/j.chembiol.2010.10.003

CDK9 inhibitors push cancer cells over the edge

Matthew W Nowicki
, Malcolm D Walkinshaw

School of Biological Sciences

Research output: Contribution to journal › Editorial › peer-review

Abstract

The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising, as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.

Original language	English
Pages (from-to)	1047-8
Number of pages	2
Journal	Chemistry and Biology
Volume	17
Issue number	10
DOIs	https://doi.org/10.1016/j.chembiol.2010.10.003
Publication status	Published - Oct 2010

Access to Document

10.1016/j.chembiol.2010.10.003

Cite this

@article{4dbb8f0cf7de4fc69e6b8318035988ce,

title = "CDK9 inhibitors push cancer cells over the edge",

abstract = "The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising, as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.",

author = "Nowicki, \{Matthew W\} and Walkinshaw, \{Malcolm D\}",

year = "2010",

month = oct,

doi = "10.1016/j.chembiol.2010.10.003",

language = "English",

volume = "17",

pages = "1047--8",

journal = "Chemistry and Biology",

issn = "1074-5521",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - CDK9 inhibitors push cancer cells over the edge

AU - Nowicki, Matthew W

AU - Walkinshaw, Malcolm D

PY - 2010/10

Y1 - 2010/10

N2 - The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising, as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.

AB - The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising, as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.

UR - https://www.scopus.com/pages/publications/78049363156

U2 - 10.1016/j.chembiol.2010.10.003

DO - 10.1016/j.chembiol.2010.10.003

M3 - Editorial

C2 - 21035725

SN - 1074-5521

VL - 17

SP - 1047

EP - 1048

JO - Chemistry and Biology

JF - Chemistry and Biology

IS - 10

ER -

CDK9 inhibitors push cancer cells over the edge

Abstract

Access to Document

Other files and links

Fingerprint

Cite this